Association Between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-analysis | Dermatology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.100.128. Please contact the publisher to request reinstatement.
1.
Schmidt  E, Zillikens  D.  Pemphigoid diseases.   Lancet. 2013;381(9863):320-332. doi:10.1016/S0140-6736(12)61140-4 PubMedGoogle Scholar
2.
Bağcı  IS, Horváth  ON, Ruzicka  T, Sárdy  M.  Bullous pemphigoid.   Autoimmun Rev. 2017;16(5):445-455. doi:10.1016/j.autrev.2017.03.010 PubMedGoogle Scholar
3.
Hammers  CM, Stanley  JR.  Mechanisms of disease: pemphigus and bullous pemphigoid.   Annu Rev Pathol. 2016;11:175-197. doi:10.1146/annurev-pathol-012615-044313 PubMedGoogle Scholar
4.
van Beek  N, Zillikens  D, Schmidt  E.  Diagnosis of autoimmune bullous diseases.   J Dtsch Dermatol Ges. 2018;16(9):1077-1091.PubMedGoogle Scholar
5.
Kridin  K, Zelber-Sagi  S, Kridin  M, Cohen  AD.  Bullous pemphigoid and neuropsychiatric medications: an influence of drugs or of underlying conditions?   J Am Acad Dermatol. Published online April 17, 2019. doi:10.1016/j.jaad.2019.03.091 PubMedGoogle Scholar
6.
Taghipour  K, Chi  C-C, Vincent  A, Groves  RW, Venning  V, Wojnarowska  F.  The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study.   Arch Dermatol. 2010;146(11):1251-1254. doi:10.1001/archdermatol.2010.322 PubMedGoogle Scholar
7.
Bernard  P, Vaillant  L, Labeille  B,  et al; Bullous Diseases French Study Group.  Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions.   Arch Dermatol. 1995;131(1):48-52. doi:10.1001/archderm.1995.01690130050009 PubMedGoogle Scholar
8.
Marazza  G, Pham  HC, Schärer  L,  et al; Autoimmune Bullous Disease Swiss Study Group.  Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study.   Br J Dermatol. 2009;161(4):861-868. doi:10.1111/j.1365-2133.2009.09300.x PubMedGoogle Scholar
9.
Baican  A, Baican  C, Chiriac  G,  et al.  Pemphigus vulgaris is the most common autoimmune bullous disease in Northwestern Romania.   Int J Dermatol. 2010;49(7):768-774. doi:10.1111/j.1365-4632.2009.04345.x PubMedGoogle Scholar
10.
Nanda  A, Dvorak  R, Al-Saeed  K, Al-Sabah  H, Alsaleh  QA.  Spectrum of autoimmune bullous diseases in Kuwait.   Int J Dermatol. 2004;43(12):876-881. doi:10.1111/j.1365-4632.2004.02292.x PubMedGoogle Scholar
11.
Bertram  F, Bröcker  E-B, Zillikens  D, Schmidt  E.  Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany.   J Dtsch Dermatol Ges. 2009;7(5):434-440. doi:10.1111/j.1610-0387.2008.06976.x PubMedGoogle Scholar
12.
Joly  P, Baricault  S, Sparsa  A,  et al.  Incidence and mortality of bullous pemphigoid in France.   J Invest Dermatol. 2012;132(8):1998-2004. doi:10.1038/jid.2012.35 PubMedGoogle Scholar
13.
Zillikens  D, Wever  S, Roth  A, Weidenthaler-Barth  B, Hashimoto  T, Bröcker  EB.  Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany.   Arch Dermatol. 1995;131(8):957-958. doi:10.1001/archderm.131.8.957 PubMedGoogle Scholar
14.
Gudi  VS, White  MI, Cruickshank  N,  et al.  Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland.   Br J Dermatol. 2005;153(2):424-427. doi:10.1111/j.1365-2133.2005.06662.x PubMedGoogle Scholar
15.
Lee  SG, Lee  HJ, Yoon  MS, Kim  DH.  Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes.   JAMA Dermatol. 2019;155(2):172-177. doi:10.1001/jamadermatol.2018.4556 PubMedGoogle Scholar
16.
Langan  SM, Smeeth  L, Hubbard  R, Fleming  KM, Smith  CJP, West  J.  Bullous pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population based cohort study.   BMJ. 2008;337(7662):a180. doi:10.1136/bmj.a180 PubMedGoogle Scholar
17.
Kridin  K, Ludwig  RJ.  The growing incidence of bullous pemphigoid: overview and potential explanations.   Front Med (Lausanne). 2018;5:220. doi:10.3389/fmed.2018.00220 PubMedGoogle Scholar
18.
Brick  KE, Weaver  CH, Savica  R,  et al.  A population-based study of the association between bullous pemphigoid and neurologic disorders.   J Am Acad Dermatol. 2014;71(6):1191-1197. doi:10.1016/j.jaad.2014.07.052 PubMedGoogle Scholar
19.
Stavropoulos  PG, Soura  E, Antoniou  C.  Drug-induced pemphigoid: a review of the literature.   J Eur Acad Dermatol Venereol. 2014;28(9):1133-1140. doi:10.1111/jdv.12366 PubMedGoogle Scholar
20.
Chen  YJ, Wu  CY, Lin  MW,  et al.  Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study.   Br J Dermatol. 2011;165(3):593-599. doi:10.1111/j.1365-2133.2011.10386.x PubMedGoogle Scholar
21.
Lloyd-Lavery  A, Chi  C-C, Wojnarowska  F, Taghipour  K.  The associations between bullous pemphigoid and drug use: a UK case-control study.   JAMA Dermatol. 2013;149(1):58-62. doi:10.1001/2013.jamadermatol.376 PubMedGoogle Scholar
22.
Kridin  K, Bergman  R.  Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients.   JAMA Dermatol. 2018;154(10):1152-1158. doi:10.1001/jamadermatol.2018.2352 PubMedGoogle Scholar
23.
Guo  J-Y, Chen  H-H, Yang  Y-C, Wu  P-Y, Chang  M-P, Chen  C-C.  The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: a retrospective cohort study.   J Diabetes Complications. 2020;34(3):107515. doi:10.1016/j.jdiacomp.2019.107515 PubMedGoogle Scholar
24.
Ruocco  V, Sacerdoti  G.  Pemphigus and bullous pemphigoid due to drugs.   Int J Dermatol. 1991;30(5):307-312. doi:10.1111/j.1365-4362.1991.tb03867.x PubMedGoogle Scholar
25.
Fellner  MJ, Katz  JM.  Occurrence of bullous pemphigoid after furosemide therapy.   Arch Dermatol. 1976;112(1):75-77. doi:10.1001/archderm.1976.01630250039012 PubMedGoogle Scholar
26.
Ameen  M, Harman  KE, Black  MM.  Pemphigoid nodularis associated with nifedipine.   Br J Dermatol. 2000;142(3):575-577. doi:10.1046/j.1365-2133.2000.03389.x PubMedGoogle Scholar
27.
Czechowicz  RT, Reid  CM, Warren  LJ, Weightman  W, Whitehead  FJ.  Bullous pemphigoid induced by cephalexin.   Australas J Dermatol. 2001;42(2):132-135. doi:10.1046/j.1440-0960.2001.00497.x PubMedGoogle Scholar
28.
Esposito  I, Moretta  G, Peris  K, De Simone  C.  Linagliptin-induced bullous pemphigoid.   Int J Dermatol. 2017;56(12):1467-1469. doi:10.1111/ijd.13705 PubMedGoogle Scholar
29.
Durdu  M, Baba  M, Seçkin  D.  A case of bullous pemphigoid induced by aspirin.   J Am Acad Dermatol. 2011;65(2):443-444. doi:10.1016/j.jaad.2010.02.032 PubMedGoogle Scholar
30.
Lee  JJ, Downham  TF  II.  Furosemide-induced bullous pemphigoid: case report and review of literature.   J Drugs Dermatol. 2006;5(6):562-564.PubMedGoogle Scholar
31.
Kanahara  SM, Agrawal  A.  Drug-induced bullous pemphigoid.   J Gen Intern Med. 2016;31(11):1393-1394. doi:10.1007/s11606-016-3679-1 PubMedGoogle Scholar
32.
Murad  AA, Connolly  M, Tobin  A-M.  Rosuvastatin-induced pemphigoid.   BMJ Case Rep. 2012:bcr1120115180. PubMedGoogle Scholar
33.
Bastuji-Garin  S, Joly  P, Lemordant  P, Sparsa  A.  Risk factors for bullous pemphigoid in the elderly: a prospective case-control study.   J Invest Dermatol. 2011;131(3):637-643. doi:10.1038/jid.2010.301PubMedGoogle Scholar
34.
Stroup  DF, Berlin  JA, Morton  SC,  et al; Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.  Meta-analysis of observational studies in epidemiology: a proposal for reporting.   JAMA. 2000;283(15):2008-2012. doi:10.1001/jama.283.15.2008 PubMedGoogle Scholar
35.
Liu  S-D, Chen  W-T, Chi C-C. Association between drug use and bullous pemphigoid. Published 2018. Accessed January 6, 2020. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42018115041
36.
Wells  GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. Published 2019. Accessed February 1, 2020. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
37.
Sterne  JAC, Savović  J, Page  MJ,  et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials.   BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898 PubMedGoogle Scholar
38.
Borenstein  M, Hedges  LV, Higgins  JPT, Rothstein  HR.  A basic introduction to fixed-effect and random-effects models for meta-analysis.   Res Synth Methods. 2010;1(2):97-111. doi:10.1002/jrsm.12 PubMedGoogle Scholar
39.
Higgins  J, Thomas J, Chandler  J, eds. Cochrane handbook for systematic reviews of interventions, version 6.0. Updated July 2019.Cochrane, 2019. Accessed May 10, 2020. http://www.training.cochrane.org/handbook
40.
Bastuji-Garin  S, Joly  P, Picard-Dahan  C,  et al.  Drugs associated with bullous pemphigoid. a case-control study.   Arch Dermatol. 1996;132(3):272-276. doi:10.1001/archderm.1996.03890270044006 PubMedGoogle Scholar
41.
Benzaquen  M, Borradori  L, Berbis  P,  et al.  Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland.   J Am Acad Dermatol. 2018;78(6):1090-1096. doi:10.1016/j.jaad.2017.12.038 PubMedGoogle Scholar
42.
Nozu  T, Mita  H.  Bullous pemphigoid and percutaneous endoscopic gastrostomy.   Intern Med. 2010;49(11):971-975. doi:10.2169/internalmedicine.49.3346 PubMedGoogle Scholar
43.
Plaquevent  M, Tétart  F, Fardet  L,  et al; French Investigators for Skin Adverse Reaction to Drugs; French Study Group on Autoimmune Bullous Skin Diseases.  Higher frequency of dipeptidyl peptidase-4 inhibitor intake in bullous pemphigoid patients than in the French general population.   J Invest Dermatol. 2019;139(4):835-841. doi:10.1016/j.jid.2018.10.045 PubMedGoogle Scholar
44.
Schaffer  C, Buclin  T, Jornayvaz  FR,  et al.  Use of dipeptidyl-peptidase IV inhibitors and bullous pemphigoid.   Dermatology. 2017;233(5):401-403. doi:10.1159/000480498 PubMedGoogle Scholar
45.
Tan  CWX, Pang  Y, Sim  B, Thirumoorthy  T, Pang  SM, Lee  HY.  The association between drugs and bullous pemphigoid.   Br J Dermatol. 2017;176(2):549-551. doi:10.1111/bjd.15195 PubMedGoogle Scholar
46.
Varpuluoma  O, Försti  A-K, Jokelainen  J,  et al.  Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study.   J Invest Dermatol. 2018;138(7):1659-1661. doi:10.1016/j.jid.2018.01.027 PubMedGoogle Scholar
47.
Varpuluoma  O, Försti  A-K, Jokelainen  J,  et al.  Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: a Finnish nationwide case-control study.   J Am Acad Dermatol. 2018;79(6):1034-1038.e5. doi:10.1016/j.jaad.2018.05.030 PubMedGoogle Scholar
48.
Varpuluoma  O, Jokelainen  J, Försti  A-K,  et al.  Drugs used for neurologic and psychiatric conditions increase the risk for bullous pemphigoid: a case-control study.   J Am Acad Dermatol. 2019;81(1):250-253. doi:10.1016/j.jaad.2019.02.017 PubMedGoogle Scholar
49.
Hung  C-T, Liu  J-S, Cheng  C-Y,  et al.  Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: a nationwide, population-based, cohort study in Taiwan.   J Dermatol. 2020;47(3):245-250. doi:10.1111/1346-8138.15195PubMedGoogle Scholar
50.
Rosenstock  J, Perkovic  V, Johansen  OE,  et al; CARMELINA Investigators.  Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial.   JAMA. 2019;321(1):69-79. doi:10.1001/jama.2018.18269 PubMedGoogle Scholar
51.
Patsatsi  A, Vyzantiadis  T-A, Chrysomallis  F, Devliotou-Panagiotidou  D, Sotiriadis  D.  Medication history of a series of patients with bullous pemphigoid from northern Greece—observations and discussion.   Int J Dermatol. 2009;48(2):132-135. doi:10.1111/j.1365-4632.2009.03839.x PubMedGoogle Scholar
52.
Park  BK, Sanderson  J, Naisbitt  D. Drugs as haptens, antigens, and immunogens. In: Pichler WJ, ed.  Drug Hypersensitivity. Karger Publishers; 2007:55-65. doi:10.1159/000104189
53.
Baum  H, Butler  P, Davies  H, Sternberg  MJ, Burroughs  AK.  Autoimmune disease and molecular mimicry: an hypothesis.   Trends Biochem Sci. 1993;18(4):140-144. doi:10.1016/0968-0004(93)90022-F PubMedGoogle Scholar
54.
Bowman  C, Delrieu  O.  Immunogenetics of drug-induced skin blistering disorders. part I: perspective.   Pharmacogenomics. 2009;10(4):601-621. doi:10.2217/pgs.09.11PubMedGoogle Scholar
55.
Ruocco  V.  Blistering eruptions caused by drugs: commentary.   Clin Dermatol. 1993;11(4):433-435. doi:10.1016/0738-081X(93)90148-6 PubMedGoogle Scholar
56.
Brenner  S, Bialy-Golan  A, Ruocco  V.  Drug-induced pemphigus.   Clin Dermatol. 1998;16(3):393-397. doi:10.1016/S0738-081X(98)00010-8 PubMedGoogle Scholar
57.
Breathnach  SM, Hintner  H.  Adverse Drug Reactions and the Skin. Blackwell; 1992.
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Original Investigation
    June 17, 2020

    Association Between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-analysis

    Author Affiliations
    • 1Department of Pharmacy, New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung Medical Foundation), New Taipei City, Taiwan
    • 2Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan
    • 3Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan
    • 4College of Medicine, Chang Gung University, Taoyuan, Taiwan
    • 5Department of Dermatology, Xiamen Chang Gung Memorial Hospital, Fujian, China
    JAMA Dermatol. 2020;156(8):891-900. doi:10.1001/jamadermatol.2020.1587
    Key Points

    Question  Is there an association between use of medications and the development of bullous pemphigoid?

    Findings  In this systematic review and meta-analysis of 13 case-control studies, 1 cohort study, and 1 randomized clinical trial with 285 884 participants, there was a significant association of the development of bullous pemphigoid with the prescribed use of aldosterone antagonists, dipeptidyl peptidase 4 inhibitors, anticholinergics, and dopaminergic medications.

    Meaning  The findings of this systematic review and meta-analysis suggest that medications should be prescribed judiciously, particularly in high-risk patients who are elderly and have disabling neurologic disorders.

    Abstract

    Importance  The association between the use of medications and the development of bullous pemphigoid (BP) is unclear.

    Objective  To assess the associations between previous exposure to certain medications and BP.

    Data Sources  For this systematic review and meta-analysis, PubMed, the Cochrane Central Register of Controlled Trials, and Embase were searched for relevant studies from inception to February 20, 2020.

    Study Selection  Case-control or cohort studies and randomized clinical trials that examined the odds or risk of BP in patients with previous medication use were included. No geographic or language limitations were imposed.

    Data Extraction and Synthesis  The Meta-analysis of Observational Studies in Epidemiology (MOOSE) guideline was followed. The Newcastle-Ottawa Scale was used to evaluate the risk of bias of included observational studies; Cochrane Collaboration’s tool was used for randomized clinical trials. Aggregate data were used to conduct a random-effects model meta-analysis if the included studies were sufficiently homogenous. Subgroup analyses were performed for use of various medications of the same category.

    Main Outcomes and Measures  Odds ratio (OR), hazard ratio, and risk ratio of bullous pemphigoid in association with medication use.

    Results  This meta-analysis included 13 case-control studies, 1 cohort study, and 1 randomized clinical trial with a total of 285 884 participants. The meta-analysis of case-control studies showed a significant association of BP with previous use of aldosterone antagonists (pooled OR, 1.75; 95% CI, 1.28-2.40), dipeptidyl peptidase 4 inhibitors (pooled OR, 1.92; 95% CI, 1.55-2.38), anticholinergics (pooled OR, 3.12; 95% CI, 1.54-6.33), and dopaminergic medications (pooled OR, 2.03; 95% CI, 1.34-3.05). One cohort study found an increased risk of BP among patients receiving dipeptidyl peptidase 4 inhibitors (hazard ratio, 2.38; 95% CI, 1.16-4.88; P = .02). One trial found a higher occurrence of BP in patients with diabetes receiving linagliptin (0.2% in diabetes group vs 0% in the placebo group).

    Conclusions and Relevance  The findings of this systematic review and meta-analysis suggest that aldosterone antagonists, dipeptidyl peptidase 4 inhibitors, anticholinergics, and dopaminergic medications are associated with BP. These medications should be judiciously prescribed, particularly in high-risk patients who are elderly and have disabling neurologic disorders.

    ×